Science Explorer Back to mapMap
Discussion
Researcher · Los Angeles Clinical Trials · United States

David Berz

David Berz publishes mostly in Oncology, Pulmonary and Respiratory Medicine and Molecular Biology, on topics such as Lung Cancer Treatments and Mutations, HER2/EGFR in Cancer Research and Cancer Immunotherapy and Biomarkers.

ORCID 0000-0001-8368-4601 OpenAlex
World rank
#1,606,327
of 7,710,434 ranked researchers
Rank in United States
#499,660
of 1,627,098
Works
133
Citations
1.9k
Citations per work
14.1
h-index
20
i10-index 32Top 23% in Oncology
David Berz

What does David Berz research?

David Berz's work is mostly in Medicine (63%), Biochemistry, Genetics and Molecular Biology (14%).

Health Sciences: 84 works · 62.9% of their workMedicine: 84 works · 62.9% of their workOncology: 40 works · 29.9% of their workPulmonary and Respiratory Medicine: 27 works · 20.3% of their workHematology: 11 works · 8.0% of their workGenetics: 6 works · 4.7% of their workEverything else: 31 works · 23.5% of their workLife Sciences: 18 works · 13.6% of their workBiochemistry, Genetics and Molecular Biology: 18 works · 13.6% of their workMolecular Biology: 12 works · 9.3% of their workCancer Research: 6 works · 4.3% of their workTHEIR WORKDavid Berz133works
Life Sciences14%Health Sciences63%

Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.

The fields and subfields, with their numbers
    1. Medicine8462.9%
  2. Everything else3123.5%
    1. Biochemistry, Genetics and Molecular Biology1813.6%
  1. 1Oncology30% of their works
  2. 2Pulmonary and Respiratory Medicine20% of their works
  3. 3Molecular Biology9% of their works
  4. 4Hematology8% of their works
  5. 5Genetics5% of their works
  6. 6Cancer Research4% of their works

Research topics

Which keywords describe David Berz's research?

The keywords of their largest research topics: Targeted Therapy, Clinical Trials, Chemotherapy, ALK Inhibitors, EGFR Mutations, Breast Cancer, HER2 and Immunotherapy.

Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.

All 21 words, with their numbers
  1. Targeted Therapy513 topics
  2. Clinical Trials432 topics
  3. Chemotherapy423 topics
  4. ALK Inhibitors331 topic
  5. EGFR Mutations331 topic
  6. Breast Cancer201 topic
  7. HER2201 topic
  8. Immunotherapy192 topics
  9. Prognostic Factors192 topics
  10. Cetuximab121 topic
  11. Immune Checkpoint Blockade121 topic
  12. KRAS Mutations121 topic
  13. PD-1 and PD-L1121 topic
  14. Genomic Profiles101 topic
  15. Small-Cell Lung Cancer101 topic
  16. CAR T Cells91 topic
  17. Chimeric Antigen Receptor91 topic
  18. Chronic Lymphocytic Leukemia91 topic
  19. Genomic Aberrations91 topic
  20. Cancer Genomics81 topic
  21. Mutational Signatures81 topic

Where does David Berz work?

David Berz's main affiliation in the publication record is Los Angeles Clinical Trials, United States.

How many publications and citations does David Berz have?

OpenAlex counts 133 works and 1,878 citations for David Berz, an h-index of 20, ranking #1,606,327 of 7,710,434 researchers worldwide on the quality score.

Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.

Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.

Discussion

Ask a question or share a note about David Berz. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.